Many types of biologics have been approved by the US Food and Drug Administration, including monoclonal antibodies (eg, adalimumab [Humira]), therapeutic proteins (eg, filgrastim [Neupogen]), and vaccines (eg, agents used for tetanus and influenza). In 2018, sales of biologics totaled approximately $125 billion, reflecting an increase of 50% from 2014 figures.1 Biologics coordinators play a central role in overcoming challenges to patient access to these agents by navigating benefits, communicating with insurance companies, and advocating for individual patients.

Read Article ›

Dermatology Practice Management
Subscribe to Dermatology Practice Management

Stay up to date with dermatology news & updates by subscribing to receive the free DPM print publications or e‑Newsletters.

DPM e-Newsletter
DPM print publication